Literature DB >> 10773176

The use of placebo control groups in the assessment of psychiatric drugs: an historical context.

P Leber1.   

Abstract

The reliable evaluation of treatments intended for the management of psychiatric illness would not be possible without the use of placebo. Other types of control groups can provide useful information, but none are capable of adducing a finding as compelling and unambiguously interpretable as a statistically significant drug-placebo difference. Its epistemological advantage notwithstanding, the ethicality of employing a placebo control group has been increasingly challenged in recent years. Many who object to the use of placebo on ethical grounds assume, incorrectly, that there are fungible alternatives to the use of placebo in the assessment of psychotropic drugs. This essay attempts to explain, within an historical context, not only why placebo is irreplaceable, but why it is often so difficult to communicate its advantages to those unfamiliar with the epistemological aims and methods of controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773176     DOI: 10.1016/s0006-3223(99)00321-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

Review 1.  Design of clinical trials of antidepressants: should a placebo control arm be included?

Authors:  J Fritze; H J Möller
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

Authors:  Robert P McMahon; Deanna L Kelly; Douglas L Boggs; Lan Li; Qiaoyan Hu; John M Davis; William T Carpenter
Journal:  Schizophr Bull       Date:  2008-01-08       Impact factor: 9.306

3.  The ophthalmologist's office: planning and practice. Patient traffic flow and use of paramedical personnel.

Authors:  H M Byron
Journal:  Int Ophthalmol Clin       Date:  1975

4.  Challenges and recommendations for placebo controls in randomized trials in physical and rehabilitation medicine: a report of the international placebo symposium working group.

Authors:  Felipe Fregni; Marta Imamura; Hsin Fen Chien; Henry L Lew; Paulo Boggio; Ted J Kaptchuk; Marcelo Riberto; Wu Tu Hsing; Linamara Rizzo Battistella; Andrea Furlan
Journal:  Am J Phys Med Rehabil       Date:  2010-02       Impact factor: 2.159

5.  Antipsychotic agents: efficacy and safety in schizophrenia.

Authors:  Arão Nogueira de Araújo; Eduardo Pondé de Sena; Irismar Reis de Oliveira; Mario F Juruena
Journal:  Drug Healthc Patient Saf       Date:  2012-11-29

6.  Ethical considerations in placebo-controlled randomised clinical trials.

Authors:  Kenneth R Kaufman
Journal:  BJPsych Open       Date:  2015-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.